Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tiziana Life Sciences Ltd
(NQ:
TLSA
)
0.9000
+0.0500 (+5.88%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tiziana Life Sciences Ltd
< Previous
1
2
3
Next >
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
March 20, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
March 17, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Highlighted in Forbes Article
March 17, 2023
Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple...
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
March 08, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
February 09, 2023
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ:TLSA). He gives his...
Via
TheNewswire.com
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
January 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
January 03, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
December 29, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
December 27, 2022
Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana to Participate in January Investor Meetings
December 16, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
December 15, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
December 14, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
December 06, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
November 23, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
November 10, 2022
-Company to host conference call via webcast at 10 am ET-
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Host Investor Call
November 04, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
November 03, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
November 02, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
October 26, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
October 19, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients
October 12, 2022
Company continues to advance foralumab in CNS-related inflammatory diseases
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 29, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
September 28, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
September 02, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.